TG Therapeutics to Present Clinical Data on TG-1101 and TGR-1202 at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma

TG Therapeutics, Inc. (Nasdaq: TGTX), today announced that clinical data for TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, the Company's once-daily PI3K delta inhibitor, will be presented at the 20th Congress of the European Hematology Association (EHA), being held from June 11 - June 14, 2015 in Vienna, Austria as well as at the 13th International Congress on Malignant Lymphoma (ICML), being held from June 17 - June 20, 2015 in Lugano, Switzerland.The Company and its study investigators will present data from the following clinical studies:TGR-1202 as a single agent in relapsed/refractory B-cell malignancies TGR-1202 in combination with TG-1101 ("1303 combination") in CLL and NHL TGR-1202 + TG-1101 + ibrutinib in B-cell malignancies TG-1101 in combination with ibrutinib in patients with relapsed/refractory CLL Additional information on the presentations can be found below:20th Congress of EHA (Vienna):Date/Time: Friday, June 12, 2015, 17:15 - 18:45 CEST Abstract Number: P327 (Poster) Presentation Title: UBLITUXIMAB + TGR-1202 DEMONSTRATES ACTIVITY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NHL AND HIGH-RISK CLL Presenter: Matthew Lunning, DO, University of Nebraska, Omaha, NE Date/Time: Saturday, June 13, 2015, 11:45 – 12:00 CEST Abstract Number: S432 (Oral Presentation) Presentation Title: TGR-1202, A NOVEL ONCE DAILY PI3K-DELTA INHIBITOR, DEMONSTRATES CLINICAL ACTIVITY WITH A FAVORABLE SAFETY PROFILE, LACKING HEPATOTOXICITY, IN PATIENTS WITH CLL AND B-CELL LYMPHOMA Presenter: Owen A. O'Connor, MD, PhD, Columbia Presbyterian Lymphoma Center, New York, NY ICML Meeting (Lugano):Date/Time: Wednesday, June 17, 2015, 17:45 CEST Abstract Number: 038 (Oral Presentation) Presentation Title: TGR-1202, A NOVEL ONCE DAILY PI3K δ INHIBITOR, DEMONSTRATES CLINICAL ACTIVITY WITH A FAVORABLE SAFETY PROFILE, LACKING HEPATOTOXICITY IN PATIENTS WITH CLL AND B-CELL LYMPHOMA Presenter: Owen A. O'Connor, MD, PhD, Columbia Presbyterian Lymphoma Center, New York, NY Date/Time: Thursday, June 18, 2015, 17:15 CEST Abstract Number: 105 (Oral Presentation) Presentation Title: UBLITUXIMAB (TG-1101), A NOVEL GLYCOENGINEERED ANTI-CD20 MAB, IN COMBINATION WITH IBRUTINIB ACHIEVES 95% ORR IN PATIENTS WITH HIGHRISK RELAPSED/REFRACTORY CLL Presenter: John Burke, MD, Rocky Mountain Cancer Center/US Oncology, Aurora, CO Date/Time: Thursday, June 18, 2015, 17:25 CEST Abstract Number: 106 (Oral Presentation) Presentation Title: THE CHEMOTHERAPY-FREE TRIPLET OF UBLITUXIMAB, TGR-1202, AND IBRUTINIB IS SAFE AND HIGHLY ACTIVE IN RELAPSED B-CELL MALIGNANCIES Presenter: Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX Date/Time: Thursday, June 18, 2015 Abstract Number: 284 (Poster) Presentation Title: UBLITUXIMAB + TGR-1202 DEMONSTRATES ACTIVITY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NHL AND HIGH-RISK CLL Presenter: Matthew Lunning, DO, University of Nebraska, Omaha, NE